Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sana Biotechnology, Inc. (NASDAQ: SANA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sana’s common stock is registered on The Nasdaq Global Select Market under the symbol SANA, and its filings offer detailed information on financial performance, capital markets activity, and progress in its engineered cell programs.
Investors can review current reports on Form 8-K in which Sana furnishes quarterly financial results, discusses non-GAAP measures, and describes material events such as equity offerings, impairment charges related to facilities, and portfolio prioritization decisions. These filings also summarize clinical and preclinical updates for programs like UP421, SC451, and in vivo CAR T candidates built on the fusogen platform, as well as interactions with regulators and key scientific publications.
Other SEC documents, including registration statements and prospectus supplements referenced in Sana’s 8-K filings, outline the terms of public offerings of common stock and pre-funded warrants, at-the-market sales programs, and related underwriting agreements. Governance-related 8-K items describe changes in board composition and senior leadership roles, with explanations of director resignations and executive transitions.
On Stock Titan, Sana’s filings are paired with AI-powered summaries that help explain the significance of each document, from quarterly results to material agreements. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while specialized views make it easier to identify items related to financing transactions, clinical disclosures, and corporate governance. This structure allows users to navigate Sana’s regulatory history and better understand how its engineered cell and gene therapy initiatives are reflected in official SEC reports.
Sana Biotechnology (NASDAQ: SANA) filed an 8-K disclosing key Q2-Q3 developments. The company estimates it held $90.1 million in cash, cash equivalents and marketable securities on 31 Jul 2025. Between 1 Apr and 6 Aug 2025 it raised $29.1 million of net proceeds through the sale of 7,441,376 common shares under its at-the-market program.
Sana will record a $40-45 million non-cash impairment in May 2025 linked to suspended build-out and planned subleases of its Bothell and Seattle facilities. Operationally, June 2025 six-month data from the investigator-sponsored UP421 trial met all primary and secondary endpoints, demonstrating insulin-producing β-cell function without immunosuppression; results were later published in NEJM. Pre-clinical candidate SC451 advanced following a favorable FDA INTERACT meeting. Conversely, Senior VP & Head of the Hypoimmune Platform Dr. Sonja Schrepfer resigned. All financial figures are unaudited and subject to change.
Sana Biotechnology (NASDAQ: SANA) filed an 8-K disclosing key Q2-Q3 developments. The company estimates it held $90.1 million in cash, cash equivalents and marketable securities on 31 Jul 2025. Between 1 Apr and 6 Aug 2025 it raised $29.1 million of net proceeds through the sale of 7,441,376 common shares under its at-the-market program.
Sana will record a $40-45 million non-cash impairment in May 2025 linked to suspended build-out and planned subleases of its Bothell and Seattle facilities. Operationally, June 2025 six-month data from the investigator-sponsored UP421 trial met all primary and secondary endpoints, demonstrating insulin-producing β-cell function without immunosuppression; results were later published in NEJM. Pre-clinical candidate SC451 advanced following a favorable FDA INTERACT meeting. Conversely, Senior VP & Head of the Hypoimmune Platform Dr. Sonja Schrepfer resigned. All financial figures are unaudited and subject to change.
Sana Biotechnology, Inc. (NASDAQ: SANA) filed a Form 8-K to disclose a material scientific milestone. On June 23 2025, the company announced positive six-month results from an investigator-sponsored, first-in-human study evaluating UP421—an allogeneic primary islet cell therapy engineered with Sana’s proprietary hypoimmune technology—in a patient with type 1 diabetes. Notably, the transplant was performed without any immunosuppression, underscoring a key differentiator of the platform. The announcement was furnished as Exhibit 99.1 to the report and no other financial metrics, earnings data or transactions were included.
The filing is limited to Item 8.01 (Other Events) and Item 9.01 (Exhibits). It confirms that the press release dated June 23 2025 is now part of the public record. No changes to guidance, capitalization or management were reported. The disclosure highlights continued progress of Sana’s cell-engineering pipeline and potentially de-risks the hypoimmune approach, but investors must await fuller clinical datasets before drawing definitive efficacy or commercial conclusions.